Galectin Therapeutics
GALT
43 hedge funds and large institutions have $2.79M invested in Galectin Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.
274% more call options, than puts
Call options by funds: $86K | Put options by funds: $23K
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
9.7% more ownership
Funds ownership: 0% → 9.7% (+9.7%)
7% less funds holding
Funds holding: 46 → 43 (-3)
19% less capital invested
Capital invested by funds: $3.43M → $2.79M (-$639K)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$108K |
| 2 |
BCA
Benchmark Capital Advisors
New York
|
+$71.1K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$28.2K |
| 4 |
LWAC
Laurel Wealth Advisors (California)
Solana Beach,
California
|
+$8.89K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$158K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$78.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$55.7K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
-$37.6K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$35K |
GALT Hedge Fund Activity: Q4 2016 in Review
43 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2016, worth a combined $2.79M — down 19% from $3.43M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GALT and 6 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 9 added.
The largest buyer was D.A. Davidson & Co, adding an estimated $108K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $158K sold.
- 43 institutional investors held Galectin Therapeutics (GALT) as of Q4 2016, down from 46 in Q3 2016.
- Funds reported $2.79M of Galectin Therapeutics stock for Q4 2016, down 19% quarter-over-quarter.
- 6 funds opened new Galectin Therapeutics positions in Q4 2016 and 8 closed out, a net change of -2 holders.
- The largest Galectin Therapeutics buyer in Q4 2016 was D.A. Davidson & Co, an estimated $108K added.
- The largest Galectin Therapeutics seller in Q4 2016 was Jacobs Levy Equity Management, an estimated $158K sold.
Based on aggregated 13F filings for Q4 2016.